Olivier Brandicourt Chief Executive Officer, Sanofi Oliver started his career as a physician working primarily on malaria – practicing medicine in the Republic of the Congo for two years. Olivier Brandicourt. The Olivier Brandicourt era at Sanofi is nearing an end, and the Paul Hudson era will begin.On Sept. 1, Brandicourt will retire, and Hudson—who was formerly president of Novartis’ pharma business—will take the reins at the French drugmaker.The change in leadership comes after Sanofi in March confirmed it was working on succession planning for Brandicourt, who took the helm at Sanofi in April 2015. The company also swapped assets with Boehringer Ingelheim in 2016, sending away its animal health group in exchange for Boehringer’s consumer healthcare business. Reproduction in the (Sanofi)New data from a recent market study shows that, while pharmacists overwhelmingly agree that recently released vancomycin dosing guidelines are important to patient safety, a minority have plans in place to adopt them. The company posted a sales decline in 2018 and cut its CEO’s pay by 25% to €7.28 million ($8.2 million), making his among the smallest compensation packages in Big Pharma. Sanofi’s chairman, Serge Weinberg, said in a statement that Hudson’s “skills and experience give him all the assets he needs to accelerate growth and lead the group's adaptation to new strategic challenges, particularly in the areas of [R&D] and digital. Únete a Facebook para conectar con Olivier Brandicourt y otras personas que tal vez conozcas. At the time, the CEO was two years away from his 65th birthday, and the company sets that age limit for its leaders. 2020 Olivier Brandicourt studied medicine in Paris and specialized in infectious diseases and tropical medicine. Olivier Brandicourt (born 13 February 1956 in Casablanca) is a French business executive and physician, and the former chief executive officer of Sanofi. All rights reserved. In recognition of his work on condensates, Dr. Hyman was recently awarded the Dewpoint Therapeutics is the first company founded to apply the emerging discipline of "Further, the new helmsman has “human values” that’ll “enable him to mobilize all the energies and increase the agility that a group such as Sanofi needs to face the new challenges of our industry and the changes in healthcare systems around the world. Dewpoint Therapeutics, the biomolecular condensates company, has announced the appointments of Olivier Brandicourt and Jürgen Eckhardt to its board of directors.. An accomplished pharmaceutical industry leader, Dr. Brandicourt has served as CEO of both Sanofi S.A. … Dewpoint is the first to pioneer a new approach to drug development informed by this understanding.”A veteran biopharmaceutical investor, Dr. Eckhardt is SVP and Head of Leaps by Bayer, the impact investment unit of Bayer AG that utilizes venture capital in order to advance breakthrough technologies and disruptive business models in healthcare and agriculture. After months of collating reader nominations and judging overseen by a panel of industry experts, we proudly present The Medicine Maker 2019 Power List, featuring 100 of the industry’s pioneers across four categories: Industry Influencers, Business Captains, Masters of the Bench, and Champions of Change.Register to access our FREE online portfolio, request the magazine in print and PARIS - June 7, 2019 - At its meeting on June 6 th of 2019, Sanofi's Board of Directors unanimously appointed Paul Hudson as Chief Executive Officer of the Group, to succeed Olivier Brandicourt who has decided to retire.. Olivier worked for 4 global pharmaceutical companies in the US, UK, Canada, Germany and France. Olivier Brandicourt está en Facebook. Olivier Brandicourt is a French businessperson who has been at the helm of 6 different companies. exclude terms.Sanofi CEO Olivier Brandicourt will retire on Sept. 1. Presently, he holds the position of Chairman for Sanofi Biotechnology SAS. Olivier Brandicourt, Actor: J'enrage de son absence. Like most websites The Medicine Maker uses cookies. Career.